This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.
Compounded GLP-1 medications
Compounded GLP-1 medications became widely available during the brand shortages. That window has largely closed. This hub explains what compounding is, what the FDA actually says, and how to evaluate a program.
Quick answer
Compounded GLP-1 drugs are prepared by pharmacies rather than manufactured as FDA-approved finished drugs. They are not FDA-approved, the FDA does not verify their quality before marketing, and routine compounding of semaglutide and tirzepatide is now restricted after the shortages resolved.
Explore this topic
Compounded semaglutide
Same molecule as Ozempic/Wegovy — with caveats
Compounded tirzepatide
Same molecule as Mounjaro/Zepbound — with caveats
Compounded GLP-1 safety
Adverse events and quality concerns
Compounded GLP-1 legality
503A/503B rules and the shortage window
503A vs 503B
The two compounding pathways explained
Verify a compounding pharmacy
A practical checklist
Regulatory contextCompounded drugs are <b>not FDA-approved</b>: the agency does not review them for safety, effectiveness or quality before they are marketed. Federal law also bars compounding drugs that are <b>essentially a copy</b> of a commercially available approved product — a bar that is lifted only while the drug is on the FDA shortage list. Both shortages are over. The FDA declared the tirzepatide shortage resolved on October 2, 2024 and the semaglutide shortage resolved on February 21, 2025, and enforcement discretion ended for all compounders between February 18 and May 22, 2025. On April 30, 2026 the FDA went further, proposing to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list on a finding of no clinical need. Routine compounding of these molecules is therefore no longer lawful on the basis that made the market — a fact most comparison sites still describe as "permanent legitimacy." It is not.
Sources
- U.S. Food and Drug Administration — approval and compounding status.
- Primary clinical literature cited on child pages.
- Our methodology and source standards.